| Tests |
Normal value |
Bortezomib- based therapy |
| Before |
After |
| 3 courses |
6 courses |
| PT [s] |
11.7-13.4 |
32.5 |
27.6 |
18.4 |
| aPTT [s] |
28.0-35.0 |
48 |
35.9 |
30.4 |
| aPTT (1+1) |
ND |
No correction |
No correction |
ND |
| TT [s] |
12.0-17.0 |
>300 |
45.5 |
10.8 |
| FII activity [%of normal value] |
50-150% |
50.1 |
ND |
ND |
| FV activity [% of normal value] |
62-139 |
16.2 |
35 |
48.9 |
| FVIII activity [% of normal value] |
50-150 |
199 |
ND |
ND |
| FX activity [% of normal value] |
77-131 |
75.8 |
ND |
ND |
| Fibrinogen concentration [g/l] |
1.8-3.5 |
4.9 |
ND |
ND |
| vWf: Ag [% of normal value, blood group non-O] |
66.1-176.3 |
140 |
ND |
ND |
| LA1/LA2 [ratio] |
<1.30 |
1.01 |
ND |
ND |
| MCF [mm] |
50-72 |
97 |
ND |
ND |
| Serum concentration |
| Monoclonal IgG (protein M) (g/l) |
|
32.0 |
20 |
1.3 |
| Total IgG (g/l) |
|
34.9 |
24.3 |
6.1 |
| Total lambda free light chain (mg/l) |
|
0.562 |
0.262 |
0.314 |
| Abbreviations: PT: Prothrombin Time; aPTT: Activated Partial Thromboplastin Time; TT: Thrombin Time; (1+1): Equal plasma volume mixing test; FII: Factor II; FV: Factor V; FVIII: Factor VIII; FX: Factor X; vWf:Ag: von Willebrand Factor Antigen; LA: Lupus Anticoagulant; MCF: Maximal Clot Firmness (EXTEM mode); ND: Not Done |
